Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Sell
46
HQL Quote, Financials, Valuation and Earnings
Last price:
$13.16
Seasonality move
:
-2.49%
Day range:
$13.07 - $13.23
52-week range:
$10.55 - $15.90
Dividend yield:
6.84%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
111.8K
Avg. volume:
97.3K
1-year change:
-14.38%
Market cap:
--
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
HQL
abrdn Life Sciences Investors
|
-- | -- | -- | -- | -- |
|
BBH
VanEck Biotech ETF
|
-- | -- | -- | -- | -- |
|
HQH
abrdn Healthcare Investors
|
-- | -- | -- | -- | -- |
|
PBE
Invesco Biotechnology & Genome ETF
|
-- | -- | -- | -- | -- |
|
THW
Tekla World Healthcare Fund
|
-- | -- | -- | -- | -- |
|
XBI
SPDR S&P Biotech ETF
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
HQL
abrdn Life Sciences Investors
|
$13.16 | -- | -- | -- | $0.43 | 6.84% | -- |
|
BBH
VanEck Biotech ETF
|
$157.92 | -- | -- | -- | $1.25 | 0.79% | -- |
|
HQH
abrdn Healthcare Investors
|
$15.77 | -- | -- | -- | $0.54 | 7.04% | -- |
|
PBE
Invesco Biotechnology & Genome ETF
|
$65.62 | -- | -- | -- | $0.13 | 0.25% | -- |
|
THW
Tekla World Healthcare Fund
|
$10.24 | -- | -- | -- | $0.12 | 9.12% | -- |
|
XBI
SPDR S&P Biotech ETF
|
$88.12 | -- | -- | -- | $0.01 | 0.04% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
HQL
abrdn Life Sciences Investors
|
-- | 1.039 | -- | -- |
|
BBH
VanEck Biotech ETF
|
-- | 0.630 | -- | -- |
|
HQH
abrdn Healthcare Investors
|
-- | 0.967 | -- | -- |
|
PBE
Invesco Biotechnology & Genome ETF
|
-- | 0.915 | -- | -- |
|
THW
Tekla World Healthcare Fund
|
-- | 0.704 | -- | -- |
|
XBI
SPDR S&P Biotech ETF
|
-- | 1.018 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
HQL
abrdn Life Sciences Investors
|
-- | -- | -- | -- | -- | -- |
|
BBH
VanEck Biotech ETF
|
-- | -- | -- | -- | -- | -- |
|
HQH
abrdn Healthcare Investors
|
-- | -- | -- | -- | -- | -- |
|
PBE
Invesco Biotechnology & Genome ETF
|
-- | -- | -- | -- | -- | -- |
|
THW
Tekla World Healthcare Fund
|
-- | -- | -- | -- | -- | -- |
|
XBI
SPDR S&P Biotech ETF
|
-- | -- | -- | -- | -- | -- |
abrdn Life Sciences Investors vs. Competitors
-
Which has Higher Returns HQL or BBH?
VanEck Biotech ETF has a net margin of -- compared to abrdn Life Sciences Investors's net margin of --. abrdn Life Sciences Investors's return on equity of -- beat VanEck Biotech ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital HQLabrdn Life Sciences Investors-- -- -- BBHVanEck Biotech ETF-- -- -- -
What do Analysts Say About HQL or BBH?
abrdn Life Sciences Investors has a consensus price target of --, signalling downside risk potential of --. On the other hand VanEck Biotech ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that abrdn Life Sciences Investors has higher upside potential than VanEck Biotech ETF, analysts believe abrdn Life Sciences Investors is more attractive than VanEck Biotech ETF.
Company Buy Ratings Hold Ratings Sell Ratings HQLabrdn Life Sciences Investors0 0 0 BBHVanEck Biotech ETF0 0 0 -
Is HQL or BBH More Risky?
abrdn Life Sciences Investors has a beta of 0.792, which suggesting that the stock is 20.833% less volatile than S&P 500. In comparison VanEck Biotech ETF has a beta of 0.764, suggesting its less volatile than the S&P 500 by 23.586%.
-
Which is a Better Dividend Stock HQL or BBH?
abrdn Life Sciences Investors has a quarterly dividend of $0.43 per share corresponding to a yield of 6.84%. VanEck Biotech ETF offers a yield of 0.79% to investors and pays a quarterly dividend of $1.25 per share. abrdn Life Sciences Investors pays -- of its earnings as a dividend. VanEck Biotech ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HQL or BBH?
abrdn Life Sciences Investors quarterly revenues are --, which are smaller than VanEck Biotech ETF quarterly revenues of --. abrdn Life Sciences Investors's net income of -- is lower than VanEck Biotech ETF's net income of --. Notably, abrdn Life Sciences Investors's price-to-earnings ratio is -- while VanEck Biotech ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for abrdn Life Sciences Investors is -- versus -- for VanEck Biotech ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HQLabrdn Life Sciences Investors-- -- -- -- BBHVanEck Biotech ETF-- -- -- --
-
Which has Higher Returns HQL or HQH?
abrdn Healthcare Investors has a net margin of -- compared to abrdn Life Sciences Investors's net margin of --. abrdn Life Sciences Investors's return on equity of -- beat abrdn Healthcare Investors's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital HQLabrdn Life Sciences Investors-- -- -- HQHabrdn Healthcare Investors-- -- -- -
What do Analysts Say About HQL or HQH?
abrdn Life Sciences Investors has a consensus price target of --, signalling downside risk potential of --. On the other hand abrdn Healthcare Investors has an analysts' consensus of -- which suggests that it could fall by --. Given that abrdn Life Sciences Investors has higher upside potential than abrdn Healthcare Investors, analysts believe abrdn Life Sciences Investors is more attractive than abrdn Healthcare Investors.
Company Buy Ratings Hold Ratings Sell Ratings HQLabrdn Life Sciences Investors0 0 0 HQHabrdn Healthcare Investors0 0 0 -
Is HQL or HQH More Risky?
abrdn Life Sciences Investors has a beta of 0.792, which suggesting that the stock is 20.833% less volatile than S&P 500. In comparison abrdn Healthcare Investors has a beta of 0.806, suggesting its less volatile than the S&P 500 by 19.424%.
-
Which is a Better Dividend Stock HQL or HQH?
abrdn Life Sciences Investors has a quarterly dividend of $0.43 per share corresponding to a yield of 6.84%. abrdn Healthcare Investors offers a yield of 7.04% to investors and pays a quarterly dividend of $0.54 per share. abrdn Life Sciences Investors pays -- of its earnings as a dividend. abrdn Healthcare Investors pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HQL or HQH?
abrdn Life Sciences Investors quarterly revenues are --, which are smaller than abrdn Healthcare Investors quarterly revenues of --. abrdn Life Sciences Investors's net income of -- is lower than abrdn Healthcare Investors's net income of --. Notably, abrdn Life Sciences Investors's price-to-earnings ratio is -- while abrdn Healthcare Investors's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for abrdn Life Sciences Investors is -- versus -- for abrdn Healthcare Investors. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HQLabrdn Life Sciences Investors-- -- -- -- HQHabrdn Healthcare Investors-- -- -- --
-
Which has Higher Returns HQL or PBE?
Invesco Biotechnology & Genome ETF has a net margin of -- compared to abrdn Life Sciences Investors's net margin of --. abrdn Life Sciences Investors's return on equity of -- beat Invesco Biotechnology & Genome ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital HQLabrdn Life Sciences Investors-- -- -- PBEInvesco Biotechnology & Genome ETF-- -- -- -
What do Analysts Say About HQL or PBE?
abrdn Life Sciences Investors has a consensus price target of --, signalling downside risk potential of --. On the other hand Invesco Biotechnology & Genome ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that abrdn Life Sciences Investors has higher upside potential than Invesco Biotechnology & Genome ETF, analysts believe abrdn Life Sciences Investors is more attractive than Invesco Biotechnology & Genome ETF.
Company Buy Ratings Hold Ratings Sell Ratings HQLabrdn Life Sciences Investors0 0 0 PBEInvesco Biotechnology & Genome ETF0 0 0 -
Is HQL or PBE More Risky?
abrdn Life Sciences Investors has a beta of 0.792, which suggesting that the stock is 20.833% less volatile than S&P 500. In comparison Invesco Biotechnology & Genome ETF has a beta of 0.810, suggesting its less volatile than the S&P 500 by 19.007%.
-
Which is a Better Dividend Stock HQL or PBE?
abrdn Life Sciences Investors has a quarterly dividend of $0.43 per share corresponding to a yield of 6.84%. Invesco Biotechnology & Genome ETF offers a yield of 0.25% to investors and pays a quarterly dividend of $0.13 per share. abrdn Life Sciences Investors pays -- of its earnings as a dividend. Invesco Biotechnology & Genome ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HQL or PBE?
abrdn Life Sciences Investors quarterly revenues are --, which are smaller than Invesco Biotechnology & Genome ETF quarterly revenues of --. abrdn Life Sciences Investors's net income of -- is lower than Invesco Biotechnology & Genome ETF's net income of --. Notably, abrdn Life Sciences Investors's price-to-earnings ratio is -- while Invesco Biotechnology & Genome ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for abrdn Life Sciences Investors is -- versus -- for Invesco Biotechnology & Genome ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HQLabrdn Life Sciences Investors-- -- -- -- PBEInvesco Biotechnology & Genome ETF-- -- -- --
-
Which has Higher Returns HQL or THW?
Tekla World Healthcare Fund has a net margin of -- compared to abrdn Life Sciences Investors's net margin of --. abrdn Life Sciences Investors's return on equity of -- beat Tekla World Healthcare Fund's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital HQLabrdn Life Sciences Investors-- -- -- THWTekla World Healthcare Fund-- -- -- -
What do Analysts Say About HQL or THW?
abrdn Life Sciences Investors has a consensus price target of --, signalling downside risk potential of --. On the other hand Tekla World Healthcare Fund has an analysts' consensus of -- which suggests that it could fall by --. Given that abrdn Life Sciences Investors has higher upside potential than Tekla World Healthcare Fund, analysts believe abrdn Life Sciences Investors is more attractive than Tekla World Healthcare Fund.
Company Buy Ratings Hold Ratings Sell Ratings HQLabrdn Life Sciences Investors0 0 0 THWTekla World Healthcare Fund0 0 0 -
Is HQL or THW More Risky?
abrdn Life Sciences Investors has a beta of 0.792, which suggesting that the stock is 20.833% less volatile than S&P 500. In comparison Tekla World Healthcare Fund has a beta of 0.865, suggesting its less volatile than the S&P 500 by 13.55%.
-
Which is a Better Dividend Stock HQL or THW?
abrdn Life Sciences Investors has a quarterly dividend of $0.43 per share corresponding to a yield of 6.84%. Tekla World Healthcare Fund offers a yield of 9.12% to investors and pays a quarterly dividend of $0.12 per share. abrdn Life Sciences Investors pays -- of its earnings as a dividend. Tekla World Healthcare Fund pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HQL or THW?
abrdn Life Sciences Investors quarterly revenues are --, which are smaller than Tekla World Healthcare Fund quarterly revenues of --. abrdn Life Sciences Investors's net income of -- is lower than Tekla World Healthcare Fund's net income of --. Notably, abrdn Life Sciences Investors's price-to-earnings ratio is -- while Tekla World Healthcare Fund's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for abrdn Life Sciences Investors is -- versus -- for Tekla World Healthcare Fund. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HQLabrdn Life Sciences Investors-- -- -- -- THWTekla World Healthcare Fund-- -- -- --
-
Which has Higher Returns HQL or XBI?
SPDR S&P Biotech ETF has a net margin of -- compared to abrdn Life Sciences Investors's net margin of --. abrdn Life Sciences Investors's return on equity of -- beat SPDR S&P Biotech ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital HQLabrdn Life Sciences Investors-- -- -- XBISPDR S&P Biotech ETF-- -- -- -
What do Analysts Say About HQL or XBI?
abrdn Life Sciences Investors has a consensus price target of --, signalling downside risk potential of --. On the other hand SPDR S&P Biotech ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that abrdn Life Sciences Investors has higher upside potential than SPDR S&P Biotech ETF, analysts believe abrdn Life Sciences Investors is more attractive than SPDR S&P Biotech ETF.
Company Buy Ratings Hold Ratings Sell Ratings HQLabrdn Life Sciences Investors0 0 0 XBISPDR S&P Biotech ETF0 0 0 -
Is HQL or XBI More Risky?
abrdn Life Sciences Investors has a beta of 0.792, which suggesting that the stock is 20.833% less volatile than S&P 500. In comparison SPDR S&P Biotech ETF has a beta of 0.917, suggesting its less volatile than the S&P 500 by 8.345%.
-
Which is a Better Dividend Stock HQL or XBI?
abrdn Life Sciences Investors has a quarterly dividend of $0.43 per share corresponding to a yield of 6.84%. SPDR S&P Biotech ETF offers a yield of 0.04% to investors and pays a quarterly dividend of $0.01 per share. abrdn Life Sciences Investors pays -- of its earnings as a dividend. SPDR S&P Biotech ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HQL or XBI?
abrdn Life Sciences Investors quarterly revenues are --, which are smaller than SPDR S&P Biotech ETF quarterly revenues of --. abrdn Life Sciences Investors's net income of -- is lower than SPDR S&P Biotech ETF's net income of --. Notably, abrdn Life Sciences Investors's price-to-earnings ratio is -- while SPDR S&P Biotech ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for abrdn Life Sciences Investors is -- versus -- for SPDR S&P Biotech ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HQLabrdn Life Sciences Investors-- -- -- -- XBISPDR S&P Biotech ETF-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
71
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 59x
Buy
51
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
71
PGY alert for Jul 18
Pagaya Technologies [PGY] is up 4.07% over the past day.
Buy
68
MCRI alert for Jul 18
Monarch Casino & Resort [MCRI] is down 0.76% over the past day.
Sell
41
NEGG alert for Jul 18
Newegg Commerce [NEGG] is up 7.58% over the past day.
